Otsuka's Taiho buys Swiss startup Araris with three ADCs nearing the clinic

Kyle LaHucik

Senior Reporter

A small Swiss drug developer is being scooped up for its pipeline of three antibody-drug conjugates that offer a next-generation approach to the area of …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Otsuka's Taiho buys Swiss startup Araris with three ADCs nearing the clinic

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Vice President, Biology & Translational Research

Gondolabio

Palo Alto, CA, USA

Trump’s HHS defends Biden-era stance on 340B rebate models

FDA staff return to White Oak campus en masse after Trump administration push

Incyte's stock sinks as pivotal skin disease data disappoint

Post-Hoc: Kennedy's anti-vaccine actions shouldn't surprise anyone

George Church spinout developing genomically recoded organisms cuts most employees

AstraZeneca taps Alteogen in deal worth more than $1.3B to make subcutaneous cancer drugs

Ot­suka's Tai­ho buys Swiss start­up Araris with three AD­Cs near­ing the clin­ic

Senior Reporter

Sign up to read this article for free.

more like this

Gondolabio

Palo Alto, CA, USA

Otsuka's Taiho buys Swiss startup Araris with three ADCs nearing the clinic